celecoxib was found to be noninferior to ibuprofen or naproxen with regard to cardiovascular safety but proved superior to both with regard to gastro intestinal (GI) safety, according to a randomised, double blind, prospective clinical trial involving 24,081 patients.
Risk of renal events with celecoxib was also found to be lower than with ibuprofen but not compared with naproxen.
CLICK HERE to access the New England Journal of Medicine study.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Nov 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Nov 16
